Acromegaly is a rare disease caused by the oversecretion of growth hormone (GH) from the pituitary gland. It is typically caused by a noncancerous tumor called a pituitary adenoma.1
Living with acromegaly can be difficult and presents challenges for patients.1 For many, just getting diagnosed with the disease may have taken years. After diagnosis, patients often face surgery to reduce or remove the tumor. For patients who can’t have surgery—and even for many patients who do—additional pharmacologic treatment is often needed to reduce GH secretion and normalize insulin-like growth factor (IGF-1) levels. Many receive long-term therapy with a somatostatin analog (SSA) such as Somatuline® Depot (lanreotide) Injection to manage their acromegaly.
The Patient Perspective
This is an actual patient and his experience may not be representative of all patients.
Somatuline Depot–Proven Effective in the Treatment of Acromegaly
Somatuline Depot is a long-term treatment for acromegaly that may help your patients move forward on their journey. With Somatuline Depot, patients get an acromegaly treatment that offers:
Proven GH and IGF-1 reduction2,3
A streamlined injection process with prefilled, ready-to-inject syringes
FDA-approved extended dosing intervals for controlled patients*2
1-on-1 support services through PACE, the Patient Access, Care & Education program
*“Controlled” is defined as GH level from >1.0 ng/mL to ≤2.5 ng/mL, normalized IGF-1 level, and satisfactory management of clinical symptoms as determined by the healthcare provider. Patients who are controlled on Somatuline Depot 60 mg or 90 mg every 4 weeks may be considered for extended dosing intervals of Somatuline Depot 120 mg every 6 or 8 weeks.